ABSTRACT. Melanoma is a malignant tumor and one of the most frequent metastatic cancers. This study was conducted to identify differential expression genes (DEGs) and single nucleotide variations (SNVs) in metastatic melanoma. We analyzed microarray data of GSE23056 downloaded from the Gene Expression Omnibus, including two normal samples (skinN1 and skinN2) and 2 metastatic melanoma samples (skinT and lymphT). We not only compared DEGs in metastatic melanoma samples with normal samples (lymphT_skinN and skinT_ skinN), but also compared DEGs between two metastatic melanoma types (lymphT_skinT). SNVs were identified by using BurrowsWheeler Aligner and Cufflinks in metastatic melanoma samples using RNA-seq. Sequence Alignment/Map tools and the ANNOVAR software were used to analyze and annotate SNVs. We identified 18 significantly common DEGs in lymphT_skinN and skinT_skinN and one common gene, YBX1, in lymphT_skinN, skinT_skinN, and lymphT_skinT. We identified 49,534, 48,118, 63,812, and 33,096 SNVs in skinN1, skinN2, 
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INTRODUCTION
Metastatic melanoma is an aggressive disease (Hodi et al., 2010) that can spread to the liver, bones, abdomen, or distant lymph nodes. The incidence of metastatic melanoma and associated number of deaths has increased substantially over the past several decades (Lens and Dawes, 2004) . Few treatments are available for metastatic melanoma; 2 therapies have been approved by the Food and Drug Administration, including high-dose interleukin-2 and dacarbaine (Comis, 1976; Atkins et al., 1999) . However, these therapies are associated with low responses and short survival times (Middleton et al., 2000; Bedikian et al., 2006) . Thus, identifying new biomarkers would be useful for developing new metastatic melanoma therapies and to facilitate drug discovery.
In metastatic melanoma, differentially expressed genes were identified between cutaneous melanomas with differing invasive phenotypes by gene expression profiling (Bittner et al., 2000) . Comparative oncogenomics enabled identification of NEDD9, which is overexpressed in 35-50% of metastatic human melanomas and may enhance invasion and metastasis in human melanoma (Kim et al., 2006) . WNT5A is expressed in human melanoma and was shown to directly affect cell motility and the invasion of metastatic melanoma (Weeraratna et al., 2002) . Clark et al. (2000) demonstrated that RhoC is overexpressed in metastatic melanoma and enhances metastasis. During the late stage of many tumors, genomic alterations are so extensive that individual genes show large amounts of variation. For example, BRAF and N-RAS mutations are common in melanoma metastases (Gorden et al., 2003) ; the BRAF mutation may account for 60% of melanomas (Smalley et al., 2006) .
Single nucleotide polymorphisms (SNPs) can be used for high-volume, rapid determination of genome-wide allelic information for a DNA sample (Lindblad-Toh et al., 2000; Kennedy et al., 2003) . Whole-genome sequencing is an effective method for identifying SNPs (Ley et al., 2008) . However, this method is very costly. RNA-seq, a new sequencing method that has been developed in recent years, uses next-generation sequencing technologies to sequence cDNA in order to determine RNA content in a sample (Nagalakshmi et al., 2010) , which can significantly reduce costs and has been widely adopted in studies of cancer (Wang et al., 2009b) . RNA-seq analysis can be used to determine differential expression of genes, single nucleotide variation (SNV) information, non-coding RNAs, gene fusions, and mRNA mutations or editing.
In this study, we identified differential expression genes (DEGs) and SNVs in normal, non-metastatic, and metastatic samples using RNA-seq. Next, we analyzed SNVs and identified the DEGs in which the SNVs were located.
MATERIAL AND METHODS

Microarray data
We downloaded microarray and sequencing data from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database. The accession number is GSE23056 (Valsesia et al., 2011) . Four samples were selected for analysis, including 2 normal samples and 2 metastatic samples. Sample information is shown in Table 1 
DEGs
We identified significantly DEGs in 2 metastatic melanoma samples compared with normal samples when the fragments per kilobase of transcript per million fragments mapped reads (FPKM) was larger than 2 in both samples, and the P value was less than 0.05. We not only searched DEGs between metastatic melanoma samples and normal samples, but also analyzed the expression levels of genes between the 2 metastatic melanoma types.
Alignment and assembly
To prevent high-quality reads from being rejected during the quality filtering or assembly processes, we trimmed bases from the poor-quality ends of reads. We first aligned our reads to the reference hg19 human genome, as well as to a library of synthetic exon junction sequences. The Burrows-Wheeler Aligner (BWA) program was used as an alignment tool to align short reads to long reference sequences with little memory and long sequences, up to 1 Mb, against mammalian-sized genomes (Li and Durbin, 2009) .
Next, we used the Cufflinks software (Trapnell et al., 2010) for transcript assembly, which was used to estimate the relative abundances of these transcripts based on default parameters. Aligned RNA-seq reads were accepted and assembled into a parsimonious set of transcripts. Cuffmerge was used to merge transcript assemblies.
Genome-wide SNV analysis
We obtained RefSeq gene annotations tables for the hg19 human genome from the University of California Santa Cruz (UCSC) Genome Bioinformatics website (http://genome. ucsc.edu). Sequence Alignment/Map (SAM) tools ) were used to parse and manipulate the alignments. SNVs were annotated using the ANNOVAR (functional annotation of genetic variants from high-throughput sequencing data) tool to examine the functional con-sequence on genes, identify variants in conserved regions, and report functional importance scores (Wang et al., 2010) .
RESULTS
DEGs
We not only analyzed DEGs in melanoma cell lines (lymphT and skinT samples) compared with normal samples (skinN sample), but also identified DEGs in the lymphT sample compared with the skinT sample. Next, we compared DEGs among lymphT_skinN, skinT_ skinN, and lymphT_skinT ( Figure 1) . A total of 289 DEGs were identified; 92, 108, and 133 DEGs were found in lymphT_skinN, skinT_skinN, and lymphT_skinT, respectively. Eighteen common DEGs were found between lymphT_skinN and skinT_skinN. The only common gene among lymphT_skinN, skinT_skinN, and lymphT_skinT was YBX1. FPKM values for YBX1 in the 2 normal skin samples were 15.5839 and 12.2385, respectively. The FPKM value was 97.4813 in the skin tumor sample and was 691.043 in the lymph tumor sample (Table 2 ). Table 2 . Fragments per kilobase of transcript per million fragments mapped reads and log2 (fold-change) of eighteen common differentially expressed genes between lymphT_skinN and skinT_skinN.
Overview of genome-wide SNVs
We identified 49,534, 48,118, 63,812, and 33,096 SNVs in skinN1, skinN2, skinT, and lymphT, respectively (Figure 2) . A Venn diagram shows the filtered sample-specific SNVs. A total of 11,697, 10,606, 11,644, and 26,173 sample-specific SNVs were identified in skinN1, skinN2, skinT, and lymphT, respectively. A total of 3196 SNVs were found only in tumor samples, indicating that these SNVs are critical factors in the development metastatic melanoma. 
Differential SNVs in DEG regions
To identify the distributions of SNVs in chromosome, we counted the density of SNVs in each sample and displayed this information using Circos (Figure 3) . We found that 98 SNVs were related to the 14 DEGs listed in Table S1 . Forty SNVs were located in the exonic region. Twenty-nine SNVs were located in the exonic regions of the 2 DEGs, major histocompatibility complex, class I, B (HLA-B) and tetraspanin 10 (TSPAN10). SNVs existing only in tumor samples were located in marvel domain containing 1 (MARVELD1), solute carrier family 16, member 3 (SLC16A3), and VAV3. MARVELD1 possessed a point mutation in the 3'-untranslated region. SLC16A3 contains a point mutation in its exon, while VAV3 contains a downstream point mutation.
DISCUSSION
In this study, we identified DEGs in metastatic melanoma and compared these DEGS with normal samples and SNVs in both tumor and normal samples using RNA-seq. In addition, we analyzed the distribution of SNVs in the genome and their relationship with DEGs.
A previous study reported that YBX1, which is involved in malignant transformation of melanocytes, could stimulate proliferation, survival, tumor invasion, and chemoresistance (Schittek et al., 2007) . Moreover, downregulation of YBX1 was hypothesized to lead to an increased rate of apoptotic cell death and a reduced rate of proliferation. Our results correspond well with this hypothesis. In our study, YBX1 was shown to be expressed in both tumor types, with its expression level varying between metastatic tumor types; the expression level is high in advanced stages, but low in early stages. Reduced YBX1 expression shows decreased resistance to chemotherapy for melanoma. This information may lead to development of a drug that can reduce the expression of YBX1 as part of melanoma therapy. Thus, YBX1 may be a biomarker for metastatic melanoma.
Mutations in noncoding regions may disrupt cis-regulatory elements, which can alter transcript levels; however, the primary causes of genetic diseases were found to be related to protein coding regions, which can alter protein form (Chepelev et al., 2009) . In our study, we identified 29 SNVs located in exonic regions of the 2 DEGs in normal samples, HLA-B and TSPAN10. HLA-B was shown to be downregulated in human melanoma (Griffioen et al., 1999a,b) . A recent study found that downregulation of TSPAN10 resulted in reduced melanoma migration (Seong et al., 2012) . These results indicate that DEGs HLA-B and TSPAN10 are related to metastatic melanoma.
SNVs only exist in tumors located in MARVELD1, SLC16A3, and VAV3. MARVELD1 was widely expressed in normal human tissues and was downregulated in multiple primary tumors derived from the breast, ovary, kidney, and liver, among others (Wang et al., 2009a) . Zeng et al. (2011) examined the function of MARVELD1 in mice and demonstrated that overexpression of mouse MARVELD1 inhibited cell proliferation, G1-phase arrest, and cell migration. In hepatocellular carcinoma, MARVELD1 is a tumor suppressor that regulates tumor growth and may be a potential biomarker for hepatocellular carcinoma therapy (Yu et al., 2012) .
SLC16A3, which belongs to the proton-linked transmembrane monocarboxylate transporter (MCT) family, is related to the transportation of metabolic monocarboxylates such as lactate, acetate, and pyruvate (Halestrap and Price, 1999) . SLC16A3 is overexpressed in breast cancers compared with normal breast tissue (Whitaker-Menezes et al., 2011) and is upregulated in bladder tumors, which showed no response to methotrexate, vinblastine, cisplatin vinblastine, doxorubicin, and cisplatin regimens (Takata et al., 2005) .
VAV3 is a member of the Vav family and is encoded by VAV3 (Faccio et al., 2005) . In prostate cancer, the VAV3 oncogene is overexpressed and regulates cell growth and androgen receptor function (Dong et al., 2006) . Lee et al. (2008) also observed overexpression of VAV3 in breast cancer specimens. It also has been reported that activation of VAV3 in tumors resulted in the development of anaplastic large cell lymphomas (Colomba et al., 2008) .
In summary, DEGs and SNVs were identified in metastatic melanoma. YBX1, HLA-B, and TSPAN10 were identified in our analysis, which is consistent with previous studies in melanoma. MARVELD1, SLC16A3, and VAV3 were newly reported for melanoma, and they may be potential biomarkers for metastatic melanoma therapy. However, further experiments are required to confirm our results.
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